Introduction Artemisinin-based combination therapies (ACTs) are recommended first-line
antimalarials for uncomplicated Plasmodium falciparum malaria. Pharmacokinetic …

Introduction: Plasmodium falciparum malaria is one of the world's most lethal infectious
diseases, commanding millions of drug administrations per year. The pharmacogenetics of …

Malaria is a vector-borne infectious disease caused by protozoan parasites of the genus
Plasmodium. If not treated appropriately, human P. falciparum malaria can quickly become …

Artemisinin is an antimalarial compound derived from the plant Artemisia annua L., also
known as sweet wormwood. According to the World Health Organization, artemisinin‐based …

The pharmacogenetics of antimalarial agents are poorly known, although the application of
pharmacogenetics might be critical in optimizing treatment. This population pharmacokinetic …

The first-line treatments for uncomplicated Plasmodium falciparum malaria are artemisinin-
based combination therapies (ACTs), consisting of an artemisinin derivative combined with …

Highlights•New targets and resistance determinants have been identified for ACT partner
drugs.•Resistance to many of the ACT partner drugs involves multifactorial mechanisms.• …

Background Despite efforts made to reduce morbidity and mortality associated with malaria,
especially in sub-Saharan Africa, malaria continues to be a public health concern that …

Introduction: Artemisinin-based combination therapy (ACT) is used extensively as first-line
treatment for uncomplicated falciparum malaria. There has been no rigorous assessment of …

Most current antimalarial drugs are combinations of an artemisinin plus a 'partner'drug from
another class, and are known as artemisinin-based combination therapies (ACTs). They are …